embodiments of the invention are not limited to the particular methodology , protocols , cell lines , vectors , and reagents described in the preferred embodiments , as these may vary . it also is to be understood that the terminology used herein is for the purpose of describing particular embodiments only , and is not intended to limit the scope of any embodiment of the present invention , which will be limited only by the appended claims . as used throughout this disclosure , the singular forms “ a ,” “ an ,” and “ the ” include plural reference unless the context clearly dictates otherwise . thus , for example , a reference to “ a host cell ” includes a plurality of such host cells , and a reference to “ an antibody ” is a reference to one or more antibodies and equivalents thereof known to those skilled in the art , and so forth . unless defined otherwise , all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs . although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention , the preferred methods , devices , and materials are now described . all publications mentioned herein are cited for the purpose of describing and disclosing the various molecules , amino acid sequences , cell lines , vectors , and methodologies that are reported in the publications and that might be used in connection with the invention . nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosures by virtue of prior invention . throughout this description , the phrase “ s provides a signal that can be detected in vivo or detected in vitro ” denotes an entity that can be imaged by itself or by reacting with another substance , and that can be detected in vivo or in vitro by a detection apparatus . more specifically , the labeling entities s include enzymes , fluorescent materials , chemiluminescent materials , biotin , avidin , radioisotopes , radionuclides , x - ray imaging agents , mri contrast agents , ultrasonography imaging elements , paramagnetic materials , and the like . suitable imaging agents that provide a detectable signal ( s ) will be described in more detail below . any binding moiety ( b ) can be used so long as it is capable of binding to lox 1 . the binding moiety may include , for example : micellular particles like ldl , oxldl and derivatives polynucleotides and derivatives such as polyinosinic acid proteins particularly including monoclonal and polyclonal antibodies , antibody fragments , diabodies , and the like protein derivatives such as glycosylated proteins polysaccharides or derivative of polysaccharides such as carrageenan and dextran sulfate peptides or peptide derivatives low molecular weight molecules the term “ fragment ” refers to a protein or polypeptide that consists of a continuous subsequence of the subject amino acid sequence and includes naturally occurring fragments such as splice variants and fragments resulting from naturally occurring in vivo protease activity . such a fragment may be truncated at the amino terminus , the carboxy terminus , and / or internally ( such as by natural splicing ). such fragments may be prepared with or without an amino terminal methionine . the term “ variant ” refers to a protein or polypeptide in which one or more amino acid substitutions , deletions , and / or insertions are present as compared to the subject amino acid sequence and includes naturally occurring allelic variants or alternative splice variants . the term “ variant ” includes the replacement of one or more amino acids in a peptide sequence with a similar or homologous amino acid ( s ) or a dissimilar amino acid ( s ). there are many scales on which amino acids can be ranked as similar or homologous . ( gunnar von heijne , sequence analysis in molecular biology , p . 123 - 39 ( academic press , new york , n . y . 1987 .) preferred variants include alanine substitutions at one or more of amino acid positions . other preferred substitutions include conservative substitutions that have little or no effect on the overall net charge , polarity , or hydrophobicity of the protein . conservative substitutions are set forth in table 1 below . other variants can consist of less conservative amino acid substitutions , such as selecting residues that differ more significantly in their effect on maintaining ( a ) the structure of the polypeptide backbone in the area of the substitution , for example , as a sheet or helical conformation , ( b ) the charge or hydrophobicity of the molecule at the target site , or ( c ) the bulk of the side chain . the substitutions that in general are expected to have a more significant effect on function are those in which ( a ) glycine and / or proline is substituted by another amino acid or is deleted or inserted ; ( b ) a hydrophilic residue , e . g ., seryl or threonyl , is substituted for ( or by ) a hydrophobic residue , e . g ., leucyl , isoleucyl , phenylalanyl , valyl , or alanyl ; ( c ) a cysteine residue is substituted for ( or by ) any other residue ; ( d ) a residue having an electropositive side chain , e . g ., lysyl , arginyl , or histidyl , is substituted for ( or by ) a residue having an electronegative charge , e . g ., glutamyl or aspartyl ; or ( e ) a residue having a bulky side chain , e . g ., phenylalanine , is substituted for ( or by ) one not having such a side chain , e . g ., glycine . other variants include those designed to either generate a novel glycosylation and / or phosphorylation site ( s ), or those designed to delete an existing glycosylation and / or phosphorylation site ( s ). variants include at least one amino acid substitution at a glycosylation site , a proteolytic cleavage site and / or a cysteine residue . variants also include peptides with additional amino acid residues before or after the subject amino acid sequence on linker peptides . for example , a cysteine residue may be added at both the amino and carboxy terminals of a subject amino acid sequence in order to allow the cyclisation of the subject amino acid sequence by the formation of a di - sulphide bond . the term “ variant ” also encompasses polypeptides that have the subject amino acid sequence with at least one and up to 25 or more additional amino acids flanking either the 3 ′ or 5 ′ end of the subject amino acid . the term “ derivative ” refers to a chemically modified protein or polypeptide that has been chemically modified either by natural processes , such as processing and other post - translational modifications , but also by chemical modification techniques , as for example , by addition of one or more polyethylene glycol molecules , sugars , phosphates , and / or other such molecules , where the molecule or molecules are not naturally attached to wild - type amino acids so derivatized . derivatives include salts . such chemical modifications are well described in basic texts and in more detailed monographs , as well as in a voluminous research literature , and they are well known to those of skill in the art . it will be appreciated that the same type of modification may be present in the same or varying degree at several sites in a given protein or polypeptide . in addition , a given protein or polypeptide may contain many types of modifications . modifications may take place anywhere in a protein or polypeptide , including the peptide backbone , the amino acid side - chains , and the amino or carboxyl termini . modifications include , for example , acetylation , acylation , adp - ribosylation , amidation , covalent attachment of flavin , covalent attachment of a heme moiety , covalent attachment of a nucleotide or nucleotide derivative , covalent attachment of a lipid or lipid derivative , covalent attachment of phosphotidylinositol , cross - linking , cyclization , disulfide bond formation , demethylation , formation of covalent cross - links , formation of cysteine , formation of pyroglutamate , formylation , gamma - carboxylation , glycosylation , gpi anchor formation , hydroxylation , iodination , methylation , myristoylation , oxidation , proteolytic processing , phosphorylation , prenylation , racemization , glycosylation , lipid attachment , sulfation , γ - carboxylation of glutamic acid residues , hydroxylation and adp - ribosylation , selenoylation , sulfation , transfer - rna mediated addition of amino acids to proteins , such as arginylation , and ubiquitination . p roteins — s tructure a nd m olecular p roperties , 2nd ed ., t . e . creighton , w . h . freeman and company , new york ( 1993 ) and wold , f ., posttranslational protein modifications : perspectives and prospects , pgs . 1 - 12 in posttranslational covalent modification of proteins , b . c . johnson , ed ., academic press , new york ( 1983 ); seifter et al ., meth . enzymol . 182 : 626 - 646 ( 1990 ) and rattan et al ., protein synthesis : posttranslational modifications and aging , ann . n . y . acad . sci . 663 : 48 - 62 ( 1992 ). the term “ derivatives ” include chemical modifications resulting in the protein or polypeptide becoming branched or cyclic , with or without branching . cyclic , branched and branched circular proteins or polypeptides may result from post - translational natural processes and may be made by entirely synthetic methods , as well . the term “ homologue ” refers to a protein that is at least 60 percent identical in its amino acid sequence of the subject amino acid sequence , as the case may be , as determined by standard methods that are commonly used to compare the similarity in position of the amino acids of two polypeptides . the degree of similarity or identity between two proteins can be readily calculated by known methods , including but not limited to those described in c omputational m olecular b iology , lesk , a . m ., ed ., oxford university press , new york , 1988 ; biocomputing : informatics and genome projects , smith , d . w ., ed ., academic press , new york , 1993 ; computer analysis of sequence data , part i , griffin , a . m ., and griffin , h . g ., eds ., humana press , new jersey , 1994 ; sequence analysis in molecular biology , von heinje , g ., academic press , 1987 ; sequence analysis primer , gribskov , m . and devereux , j ., eds ., m stockton press , new york , 1991 ; and carillo h . and lipman , d ., siam , j . applied math ., 48 : 1073 ( 1988 ). preferred methods to determine identity are designed to provide the largest match between the sequences tested . methods to determine identity and similarity are codified in publicly available computer programs . preferred computer program methods useful in determining the identity and similarity between two sequences include , but are not limited to , the gcg program package ( devereux , j ., et al ., nucleic acids research , 12 ( 1 ): 387 ( 1984 )), blastp , blastn , and fasta , atschul , s . f . et al ., j . molec . biol ., 215 : 403 - 410 ( 1990 ). the blast x program is publicly available from ncbi and other sources ( blast manual , altschul , s ., et al ., ncbi nlm nih bethesda , md . 20894 ; altschul , s ., et al ., j . mol . biol ., 215 : 403 - 410 ( 1990 ). by way of example , using a computer algorithm such as gap ( genetic computer group , university of wisconsin , madison , wis . ), the two proteins or polypeptides for which the percent sequence identity is to be determined are aligned for optimal matching of their respective amino acids ( the “ matched span ”, as determined by the algorithm ). a gap opening penalty ( which is calculated as 3 × ( times ) the average diagonal ; the “ average diagonal ” is the average of the diagonal of the comparison matrix being used ; the “ diagonal ” is the score or number assigned to each perfect amino acid match by the particular comparison matrix ) and a gap extension penalty ( which is usually { fraction ( 1 / 10 )} times the gap opening penalty ), as well as a comparison matrix such as pam 250 or blosum 62 are used in conjunction with the algorithm . a standard comparison matrix ( see dayhoff et al . in : atlas of protein sequence and structure , vol . 5 , supp . 3 for the pam250 comparison matrix ; see henikoff et al ., proc . natl . acad . sci usa , 89 : 10915 - 10919 [ 1992 ] for the blosum 62 comparison matrix ) also may be used by the algorithm . the percent identity then is calculated by the algorithm . homologues will typically have one or more amino acid substitutions , deletions , and / or insertions as compared with the comparison subject amino acid , as the case may be . the term “ fusion protein ” or “ fusion polypeptide ” refers to a protein where one or more of the subject amino acid sequences are recombinantly fused or chemically conjugated ( including covalently and non - covalently ) to a protein such as ( but not limited to ) an antibody or antibody fragment like an f ab fragment or short chain fv . the term “ fusion protein ” or “ fusion polypeptide ” also refers to multimers ( i . e . dimers , trimers , tetramers and higher multimers ) of peptides . such multimers comprise homomeric multimers comprising one subject peptide , heteromeric multimers comprising more than one subject peptide , and heteromeric multimers comprising at least one subject peptide and at least one other protein . such multimers may be the result of hydrophobic , hyrdrophilic , ionic and / or covalent associations , bonds or links , may be formed by cross - links using linker molecules or may be linked indirectly by , for example , liposome formation . various fusion proteins known to bind to the human lox - 1 receptor are disclosed in ep 1046652a1 , the disclosure of which is incorporated by reference herein in its entirety . the term “ peptide mimetic ” or “ mimetic ” refers to biologically active compounds that mimic the biological activity of a peptide or a protein but are no longer peptidic in chemical nature , that is , they no longer contain any peptide bonds ( that is , amide bonds between amino acids ). here , the term peptide mimetic is used in a broader sense to include molecules that are no longer completely peptidic in nature , such as pseudo - peptides , semi - peptides and peptoids . examples of peptide mimetics in this broader sense ( where part of a peptide is replaced by a structure lacking peptide bonds ) are described below . whether completely or partially non - peptide , peptide mimetics according to this invention provide a spatial arrangement of reactive chemical moieties that closely resemble the three - dimensional arrangement of active groups in the subject peptide on which the peptide mimetic is based . as a result of this similar active - site geometry , the peptide mimetic has effects on biological systems that are similar to the biological activity of the subject peptide . the peptide mimetics of this invention are preferably substantially similar in both three - dimensional shape and biological activity to the subject peptides described herein . examples of methods of structurally modifying a peptide known in the art to create a peptide mimetic include the inversion of backbone chiral centers leading to d - amino acid residue structures that may , particularly at the n - terminus , lead to enhanced stability for proteolytical degradation without adversely affecting activity . an example is given in the paper “ tritriated d - ala 1 - peptide t binding ”, smith c . s . et al ., drug development res ., 15 , pp . 371 - 379 ( 1988 ). a second method is altering cyclic structure for stability , such as n to c interchain imides and lactames ( ede et al . in smith and rivier ( eds .) “ peptides : chemistry and biology ”, escom , leiden ( 1991 ), pp . 268 - 270 ). an example of this is given in conformationally restricted thymopentin - like compounds , such as those disclosed in u . s . pat . no . 4 , 457 , 489 ( 1985 ), goldstein , g . et al ., the disclosure of which is incorporated by reference herein in its entirety . a third method is to substitute peptide bonds in the subject peptide by pseudopeptide bonds that confer resistance to proteolysis . a number of pseudopeptide bonds have been described that in general do not affect peptide structure and biological activity . one example of this approach is to substitute retro - inverso pseudopeptide bonds (“ biologically active retroinverso analogues of thymopentin ”, sisto a . et al in rivier , j . e . and marshall , g . r . ( eds ) “ peptides , chemistry , structure and biology ”, escom , leiden ( 1990 ), pp . 722 - 773 ) and dalpozzo , et al . ( 1993 ), int . j . peptide protein res ., 41 : 561 - 566 , incorporated herein by reference ). according to this modification , the amino acid sequences of the peptides may be identical to the sequences of the subject amino acid sequence , except that one or more of the peptide bonds are replaced by a retro - inverso pseudopeptide bond . preferably the most n - terminal peptide bond is substituted , since such a substitution will confer resistance to proteolysis by exopeptidases acting on the n - terminus . further modifications also can be made by replacing chemical groups of the amino acids with other chemical groups of similar structure . another suitable pseudopeptide bond that is known to enhance stability to enzymatic cleavage with no or little loss of biological activity is the reduced isostere pseudopeptide bond ( couder , et al . ( 1993 ), int . j . peptide protein res ., 41 : 181 - 184 , incorporated herein by reference in its entirety ). thus , the amino acid sequences of these peptides may be identical to the sequences of the subject amino acid sequence , except that one or more of the peptide bonds are replaced by an isostere pseudopeptide bond . preferably the most n - terminal peptide bond is substituted , since such a substitution would confer resistance to proteolysis by exopeptidases acting on the n - terminus . the synthesis of peptides with one or more reduced isostere pseudopeptide bonds is known in the art ( couder , et al . ( 1993 ), cited above ). other examples include the introduction of ketomethylene or methylsulfide bonds to replace peptide bonds . peptoid derivatives represent another class of peptide mimetics that retain the important structural determinants for biological activity , yet eliminate the peptide bonds , thereby conferring resistance to proteolysis ( simon , et al ., 1992 , proc . natl . acad . sci . usa , 89 : 9367 - 9371 , incorporated herein by reference in its entirety ). peptoids are oligomers of n - substituted glycines . a number of n - alkyl groups have been described , each corresponding to the side chain of a natural amino acid ( simon , et al . ( 1992 ), cited above ). some or all of the amino acids of the subject molecules may be replaced with the n - substituted glycine corresponding to the replaced amino acid . the term “ peptide mimetic ” or “ mimetic ” also includes reverse - d peptides and enantiomers . the term “ reverse - d peptide ” refers to a biologically active protein or peptide consisting of d - amino acids arranged in a reverse order as compared to the l - amino acid sequence of the subject peptide . the term “ enantiomer ” refers to a biologically active protein or peptide where one or more the l - amino acid residues in the amino acid sequence of a subject peptide is replaced with the corresponding d - amino acid residue ( s ). a “ composition ” as used herein , refers broadly to any composition containing a described molecule , peptide , or amino acid sequence . the composition may comprise a dry formulation , an aqueous solution , or a sterile composition . compositions comprising the molecules described herein may be stored in freeze - dried form and may be associated with a stabilizing agent such as a carbohydrate . in use , the composition may be deployed in an aqueous solution containing salts , e . g ., nacl , detergents , e . g ., sodium dodecyl sulfate ( sds ), and other components , e . g ., denhardt &# 39 ; s solution , dry milk , salmon sperm dna , etc . an embodiment of the present invention relates to molecules useful in detecting or imaging atherosclerotic tissue by binding to lox - 1 . these molecules preferably have the following characteristics : contain a moiety that binds to lox - 1 in the presence of human fluids with adequate specificity such that atherosclerotic tissue may be differentiated from healthy tissue ; and contain a signal moiety that can be detected . lox - 1 or lectin - like oxidized ldl receptor was recently identified as a receptor on endothelial cells for oxldl ; it mediates the internalization of oxldl by endothelial cells and is distinct from macrophage scavenger receptors such as those described in wo 2002 / 06771 , ( sawamura , t . nature 1997 386 : 73 - 77 ). lox - 1 also is expressed on macrophages and may play a role in oxldl recognition / internalization on these cells ( yoshida , h . et al ., biochem . j . 1998 334 : 9 - 13 ). lox - 1 is nearly undetectable in healthy human aorta samples but is found in atherosclerotic plaque , particular early lesions that are unlikely to be detectable by other means ( kataoka , h . et al ., circulation 1999 99 : 3110 - 3117 ). an antibody to lox - 1 has been described as being useful to treat atherosclerosis by preventing binding of oxldl to lox - 1 ( wo0164862 ). recent work suggests that recognition of oxldl by lox - 1 is a critical early step in expression of adhesion receptors on endothelial cells . these receptors are believed to be responsible for attracting monocytes to the early atherosclerotic plaque . the monocytes penetrate the endothelial , differentiate into macrophages and can end up as foam cells in the growing plaque . finally , peptides were developed that bind to lox - 1 using phage display technology ( white , s . et al ., hypertension 2001 37 : 449 - 455 ). various species of lox - 1 have been isolated and sequenced revealing relatively significant dissimilarity interspecies ( chen , m ., et al ., j . biochem ., 355 : 289 - 95 ( 2001 ). u . s . pat . nos . 5 , 962 , 260 and 6 , 197 , 937 , the disclosures of which are incorporated by reference herein in their entirety , disclose the amino acid sequences of human and bovine lox - 1 . using the techniques disclosed in these documents , and the guidelines provided herein , those skilled in the art are capable of isolating lox - 1 from any species , and creating molecules such as antibodies that bind to the human lox - 1 . thus , in the above molecule , the moiety that binds to lox - 1 can be synthesized using known techniques , given the known amino acid sequence of the lox - 1 polypeptide . moieties that bind only specific portions of lox - 1 also can be synthesized given the known and / or expected antigenic determinant or epitope binding site . unlike known moieties that bind to lox - 1 , the inventive moieties are designed to bind to lox - 1 in the presence of human fluids ( in vivo or in vitro ) with sufficient specificity such that tissue in which lox - 1 has been overexpressed ( e . g ., atherosclerotic tissue ) may be differentiated from healthy tissue . the inventive molecules also are bound , again in the presence of human fluids , to a signal moiety with sufficient specificity to enable detection using imaging techniques . moieties that bind to lox - 1 include , for example antibodies to lox - 1 , such as those described in wo 0164862 , and u . s . pat . no . 6 , 197 , 937 , macromolecules other than antibodies such as poly i and carrageenan ( arterioscler thromb vasc biol . 1998 18 : 1541 - 1547 . ), peptides such as those described in white , s . et al . hypertension 2001 37 449 - 455 , peptide mimetics and organic molecules that satisfy the criteria above . it is preferred in an embodiment of the present invention , however , that the moieties that bind to lox - 1 do not include peptides . preferably , the agents that bind lox - 1 are selected from antibodies , proteins , glycosylated proteins , biomolecules , polysaccharides , peptidomimetics , low molecular weight organic compounds , and mixtures , derivative , fragments , homologues , and variants thereof . a suitable protein includes heat shock protein 70 ( hsp70 ). delneste , y ., et al ., “ involvement of lox - 1 in dendritic cell - mediated antigen cross presentation ,” immunity , 17 ( 3 ), pp 353 - 62 ( 2002 ). the methods disclosed in the above documents can be used to generate a plurality of agents capable of binding lox - 1 . these agents then can be screened as described herein by reacting them with a plurality of signal moieties and optional linking ligands , and tested to assess their efficacy in binding both the lox - 1 polypeptide and the signal moieties . while peptides are not preferred for use in certain embodiments of the invention , if a peptide were used , it is preferred that the peptide have one or more peptidic sequences selected from the group consisting of lsippka , fqtppql , ltpatai , and mixtures , fragments , fusion peptides , derivatives , variants , and homologues thereof . a number of methods can be used to screen and evaluate the binding affinity of different ligands . one method for example includes fluorescent based in vitro experiments . cell - based assays can simultaneously yield information on the amount of signal generating entity necessary for detection , and therefore required for conjugation to ligands . in the case of the peptidic ligands , a fluorescent dye preferably is attached to the n - terminus of the peptide via a flexible linker , such as the amino acid sequence kkgg ( k = lysine , g = glycine ). in the event that the n - terminus is linked to a signaling moiety with no further functional ends for dye attachment , the dye also can be attached via the side - chain amine of a k residue incorporated into the sequence ( e . g . in the linker ). regardless of the type of screening assay used , ( e . g ., a generic in vitro model ), it first is assumed that the amount of lox - 1 on the surface of a substrate is known , whether it be cells or some other substrate . in a multi - well transparent plate , lox - 1 is present ( either as pure lox - 1 protein or expressed on cells ) uniformly across the wells . labeled ligands then can be added and incubated for an optimized amount of time in the different wells . the wells then are washed thoroughly with a buffer , such as phosphate buffered saline ( pbs ), and the plate then imaged while shining a laser to excite and initiate fluorescence of the dye attached to the ligands . the fluorecent intensity from each well , and thus the degree of different ligand binding , can be quantified . to obtain the absolute number of ligand bound , the signal preferably is further calibrated by obtaining the fluorescent intensity of a known quantity of dye - conjugated ligand under similar conditions of the binding assay . if the number of lox - 1 molecule is known , and the amount of bound ligands determined , dissociation constants to evaluate ligand - binding affinity can be calculated . different ligands can thus be screened quantitatively for their binding affinity . the number of bound ligands per cells also is capable of providing information on parameters required to obtain a detectable signal from a signal - generating entity conjugated to the ligands . images in the assay may be acquired using a laser confocal microscope or an imager . for example , images of peptides bound to cells can be obtained using a laser confocal microscope as follows : hcae cells can be grown on high quality borosilicate 8 - chambered glass slides ( electron microscopy sciences , fort washington , pa .). then , about 10 μl of 1 mg / ml of an aqueous solution of a labeled peptide can be added to the cells and incubated for 1 hour . subsequently , the cells preferably are washed with hbss buffer three times . the cells then can be fixed with 4 % formaldehyde solution over 10 minutes . after a final wash with buffer , the slide is imaged . images preferably are acquired using an olympus laser scanning confocal microscope , model fluoview 300 , using ar - ion laser ( selecting 488 nm line ) and a 510 - nm long - pass filter . images can be acquired using two channels : reflected light and fluorescent mode channel , or an overlay of both channels . for higher throughput screening the method described above can be extended : a 96 - well plate may replace the 8 - well slides and a biorad imager , model fx proplus , replace the confocal microscope . for example , images of fluorescein - labeled polyclonal antibody bound to cells can be obtained using an imager , whereby hcae cells can be laid on and grown in wells on a standard commercial 96 - well plate ( becton - dickenson , franklin lakes , n . j .). then , about 10 μl of 1 mg / ml labeled antibody aqueous solution can be added to the cells and incubated for 1 hour . subsequently , the cells preferably are washed with pbs buffer three times . after a final wash with buffer , the slide can be imaged using the biorad imager selecting “ fluorescein ” as the fluorophore . any signal moiety can be used so long as it is capable of binding the binding moiety and generating a detectable signal . suitable signal moieties include a luminescent dye , a radionuclide , a near infrared dye , a magnetically active isotope , a superparamagnetic particle , a metal ion having a z value of greater than 50 , an encapsulated species , and a combination thereof . the signal moiety may include , for example : dyes , fluorescent dye , chemiluminescent dyes for optical imaging , histology ; molecules containing high - z elements , such as iodine , for x - ray imaging , computed tomography ( ct ); gas - filled microbubbles , fluorocarbon filled micelles for ultrasonography ( us ); paramagnetic ions , such as chelated gd +++ , or superparamagnetic particles such as superparamagnetic iron oxide nanoparticles ( spio ) for magnetic resonance imaging ( mri ); or radionuclides such as 99mtc for single photon emission computed tomography ( spect ) or 18 f for positron emission tomography ( pet ). particularly preferred signal moieties include fluorescein , 11 c , 18 f , 52 fe , 62 cu , 64 cu , 67 cu , 67 ga , 68 ga , 86 y , 89 zr , 94m tc , 94 tc , 99m tc , 111 in , 123 i , 124 i , 125 i , 131 i , 154 - 158 gd and 175 lu , superparamagnetic iron oxide nanoparticles , heavy metal ions , gas - filled microbubbles , optical dyes , porphyrins , texaphyrins , highly iodinated organic compounds chelates thereof , polymers containing at least one of the aforementioned components , endoedral fullerenes containing at least one of the aformentioned , and mixtures thereof . even more preferably , the signal moieties are 18 f for pet , superparamgnetic iron oxide nanoparticles ( spio ) for mri , chelated gd , i , and y . most preferably , the signal moiety is 18 f for pet . 18 f - fluoride can be obtained from cyclotrons after bombardment of 18 o - enriched water with protons . typically , the enriched water containing 18 f - fluoride is treated with a base having a counter - ion that is any alkali metal cation ( m + ), such as potassium or another monovalent ion as well as a chelate for m + , such as kryptofix 222 . the water can be evaporated off to produce a residue of chelate m - 18 f , which can be taken up in an organic solvent for further use . the purpose of the chelate is to solubilize the m - 18 f in the organic solvent and confer nucleophilicity to the 18 f - fluoride . instead of a chelate and m + , a quaternary ammonium salt , phosphonium salt or guandinium may be used to solubilize the 18 f - fluoride in the organic solvent and confer nucleophilic reactivity to the 18 f - fluoride . potassium is generally used as a counter - ion . because fluoride is the most electronegative element , it has a tendency to become hydrated and lose its nucleophilic character . to minimize this , the labeling reaction preferably is performed under anhydrous conditions . for example , fluoride ( as potassium fluoride or as a complex with any of the other counter - ions discussed above ) can be placed in organic solvents , such as acetonitrile or thf . with the assistance of agents that bind to the counter - ion , such as kryptofix 2 . 2 . 2 ( 4 , 7 , 13 , 16 , 21 , 24 - hexaoxa - 1 , 10 - diazabicyclo [ 8 . 8 . 8 ]- hexacosane ), the fluoride ion is very nucleophilic in these solvents . the remaining portion of the chelate molecule of the invention then can be added to the solvent and the chelate thereby labeled with the 18 f . using the guidelines provided herein , those skilled in the art are capable of labeling the ligands of the present invention with 18 f . alternatively , labeling may be accomplished through the use of 18 f - f 2 or electrophilic fluorinating agents derived from 18 f - f 2 . other suitable signaling moieties include magnetically active isotopes , such a paramagnetic ions , isotopes of gadolinium , and polymers containing such compounds . nanoparticles of iron oxides or elemental iron also can be used as superparamagnetic signaling agents . components having a z value greater than about 50 , such as iodine and bismuth also can be used . suitable signal moieties further include encapsulated species such as micelles , liposomes , polysomes , and gas - filled microbubles . l is simply any moiety , which connects the signal moiety s to the binding moiety b . in the case of 18 f or 11 c a linker may not be necessary ; the radioisotope can be directly attached to b via a covalent bond . in many cases it is preferred to include l in order to attach s to b . that is , n in the equation for the molecule of the invention is 1 . preferred linking agents include polypeptides , proteins , and small organic moieties . for example , lysine - glycine analogs , derivatives and variants can be used , conventional chelators such as cyclohexyl alanine , dtpa , 1 , 4 , 7 - triaza - cyclononane - n , n ′, n ″- triacetic acid ( nota ), p - bromoacetamido - benyl - tetraethylaminetetraacetic acid ( teta ), 1 , 4 , 7 , 10 - tetraazacyclododecanetetraacetic acid ( dota ), and combinations thereof . a preferred linking agent could be a lysine - glycine derivative such as kkgg organic moieties having a valence of at least 2 are useful as l in the above formula , including small organic moieties such as benzoate or propionate ( fig1 ). the organic radical may be covalently bound to both s and b , or it may be ionically bound to s , b , or both s and b . the organic moiety suitable for use as the linking agent typically has from about 1 to about 10 , 000 carbon atoms , and may include , an organic radical selected from the group consisting of alkylene , arylene , cycloakylene , aminoaklylene , aminoarylene , aminocycloalkylene , thioalkylene , thioarylene , thiocycloalkylene , oxyalkylene , oxyarylene , oxycycloalkylene , acylalkylene , acylarylene , acylcycloalkylene units , and combinations thereof . a particularly preferred acylarylene unit is a 4 - acylphenylene group having the structure below : other suitable linking agents including metal chelating agents , such as one or more of dtpa , 1 , 4 , 7 - triaza - cyclononane - n , n ′, n ″- triacetic acid ( nota ), p - bromoacetamido - benyl - tetraethylaminetetraacetic acid ( teta ), 1 , 4 , 7 , 10 - tetraazacyclododecanetetraacetic acid ( dota ), edta , and chxa . it is preferred that the metal chelating agents be capable of binding to at least one metal selected from cations of 52 fe , 62 cu , 64 cu , 67 cu , 67 ga , 68 ga , 86 y , 89 zr , 94m tc , 94 tc , 99m tc , 111 in , 154 - 158 gd , and 175 lu . as appreciated by those skilled in the art , various linking agents are used with certain signal moieties . for example , signal generating moieties , such as 64cu , typically require a linking ligand , whereas 18 f does not . in addition , labeled prosthetic groups such as 18 f - fluoropropionate or 18 f - fluorobenzoate ( fig1 ) can be used such that , once prepared , they can be conjugated to the peptide via active ester conjugation . those skilled in the art are capable of synthesizing a suitable linking agent , if needed , together with a suitable signaling moiety , using the guidelines and synthesis techniques provided herein . the labeled ligands of embodiments of the present invention can be used as a diagnostic to assist in imaging a targeted tissue that is suspected of overexpressing lox - 1 . the method of diagnosis therefore includes first administering to a subject a composition containing the labeled ligand of the invention . the method also optionally includes administering a clearing agent to assist in clearing any unbound antibody and fragments thereof from circulation . depending on the particular label that has been labeled to the ligand , the appropriate imaging technique is employed to image the targeted tissue . for example , when 18 f is used as the labeling agent pet imaging is conducted . the imaging method can be used as a diagnostic to detect the presence of lox - 1 in human tissue . in addition , the imaging method can be repeated over a number of days to provide a quantitative assessment of the degree of growth or expression of the lox - 1 polypeptide . embodiments of the invention also encompass a composition comprising the labeled ligands , as well as a kit for imaging a targeted tissue . the kit preferably comprises a composition comprising the labeled ligand of the invention , or optionally , comprises two compositions ; one containing an 18 f precursor , and the other containing the remaining portion of the labeled ligand . these two compositions can be mixed just prior to administration to the subject , thereby preserving the life of the 18 f radionuclide . methods of synthesizing peptidic ligand linkers ( l ) that are useful in labeling moieties ( b ) that recognize lox - 1 , as well as methods of directly labeling binding agents that bind lox - 1 are described hereinafter . peptides can be synthesized using standard solid phase techniques with n α - fmoc - protected amino acids ( sheppard , r . c ., peptides , north - holland publishing company , amsterdam ( 1973 )) using 2 , 4 - dimethoxybenzhydrylamine resin ( rink amide am ) on a 25 μmole scale ( fmoc = fluorenylmethoxycarbonyl ). the peptides can be synthesized using a rainin / protein technology symphony solid phase peptide synthesizer ( woburn , mass .). prior to any reaction chemistry , the resin preferably is swelled for one hour in methylene chloride , and subsequently exchanged out with dmf ( dimethylformamide ) over half - hour or more . each coupling reaction to synthesize the peptide can be carried out at room temperature in dmf with five equivalents of amino acid . reaction times usually are from about 20 minutes to about 3 hours , more preferably about 45 minutes , 1 hour for residues that were expected to be difficult to couple ( for example , coupling isoleucine , i , to proline , p , in the ipp sequence ). the preferred coupling reagent used is hbtu ( o - benzotriazolyl - 1 - yl - n , n , n ′, n ′- tetramethyluronium hexafluorophosphate ), with nmm ( n - methylmorpholine ) as the base . during each coupling step , the coupling agent preferably is delivered at a scale of five equivalents relative to the estimated resin capacity , and reaction carried out in 2 . 5 ml of 0 . 4 m nmm solution in dmf . it is preferred that the coupling reactions do not perturb the side - chains of the amino acids because the acids typically were protected with acid labile groups if reactive groups were present . for example , tyrosine , threonine and serine side chains can be protected as the corresponding tert - butyl ethers . glutamic acid side chains can be protected as the corresponding tert - butyl ester . lysine and ornithine side chains can be boc protected . glutamine side chains also may be protected as the γ - triphenylmethyl derivative , and the arginine side chain protected as the 2 , 2 , 5 , 7 , 8 - pentamethyl - chromane - 6 - sulfonyl derivative . following each coupling reaction , the n - terminal fmoc - protected amine preferably is deprotected by applying 20 % piperidine in dmf twice at room temperature for approximately 15 minutes . after the addition of the last residue the resin , still on the peptide synthesizer , preferably is rinsed thoroughly with dmf and methylene chloride . the signaling moiety ( s ) can be attached to the peptide for ultimate attachment to the binding moiety ( b ), or directly to b . for example , to couple the fluorescein dye , 5 ( 6 )- carboxyfluorescein , to the n - terminus of a synthesized peptide , the dye , hbtu and nmm preferably are added to the resin in the same manner as the amino acids described above . after the reaction , the resin preferably is thoroughly washed with dmf and methylene chloride and dried under a stream of nitrogen . a mixture containing 1 ml tfa , 2 . 5 % tsp ( triisopropylsilane ) and 2 . 5 % water can be used to cleave the peptides from the resin . the resin and mixture preferably are stirred at room temperature for approximately 3 to 4 hours . the resin beads then can be filtered off using glass wool , followed by rinsing with 2 - 3 ml of tfa . the peptide then preferably is precipitated with ice - cold ether ( 40 ml ) and centrifuged ( e . g ., at 3000 - 4000 rpm ) until the precipitate formed a pellet at the bottom of the centrifuge tube . the ether can be decanted , and the pellet resuspended in cold ether ( 40 ml ) and centrifuged again — the process can be repeated two to three times . during the final wash 10 ml of millipore water preferably is added to 30 ml of cold ether , and the mixture was centrifuged again . the ether then can be decanted , the aqueous layer containing the crude peptide then can be transferred to a round bottom flask for lyophilization . crude yields for peptide synthesis were usually approximately 90 %. no unlabeled peptide was typically observed . peptides preferably are purified by reverse phase semipreparative or preparative hplc with a c4 - silica column ( vydac , hesperia , calif .). the peptide chromatograms can be monitored at 220 nm , which corresponds to the absorption of the amide chromophore . monitoring at 495 nm also can be observed to ensure the presence of the fluorescein dye on the peptide . it is preferred to use a solvent system including ch 3 cn / tfa ( acetonitrile / trifluoroacetic acid ; 100 : 0 . 01 ) and h 2 o / tfa ( water / trifluoroacetic acid ; 100 : 0 . 01 ) eluents at flow rates of 3 ml / min and 10 ml / min for semipreparative and preparative , respectively . dissolved crude peptides in millipore water can be injected at a scale of 1 . 5 mg and 5 - 10 mg peptide for semipreparative or preparative , respectively . the chromatogram shape was analyzed to ensure good resolution and peak shape . gradient conditions for all peptides were typically 5 to 50 % of ch 3 cn / tfa ( 100 : 0 . 01 ) in 30 minutes . purified peptide identity was confirmed by matrix - assisted laser desorption time - of - flight mass spectroscopy . a polyclonal antibody , for example , that recognizes lox - 1 can be labeled using active ester chemistry in conjunction with the description herein as follows . an aliquot containing 250 μg ( 166 μl ) of the intact antibody ( immunoglobulin g , igg ) preferably is transferred to a 1 . 5 ml eppendorf tube and maintained at 0 ° c . the solution then can be treated with nahco 3 ( 1m , 20 μl ) and gently inverted . in a separate tube , a solution of an active ester compound preferably is prepared in either pbs or dmf using standard peptide synthesis techniques , such as those described previously . specifically , a carboxylate containing labeling moeity can be activated using n - hydroxysuccimide , a water - soluble carbodiimide such as edc ( 1 -( 3 - dimethylaminopropyl )- 3 - ethylcarbodiimide ), and a base such as nahco 3 or n - methylmorpholine ( nmm ). the antibody solution then preferably is treated with 5 , 20 or 50 molar equivalents of the active ester solution . concentrations of organic solvents used preferably are minimized , generally below 15 % by volume . the reaction vessel then can be permitted to warm to about room temperature over a 1 hour period and then gently inverted every 15 minutes to assure mixing . during this time a pd - 10 column ( amersham biosciences , piscataway , n . j .) preferably is equilibrated with 25 ml of pbs and eluted until the sorbent bed is exposed . the entire reaction mixture then can be transferred to the sorbent bed and eluted with pbs . the fast moving component contains the protein and appears at an approximate eluted volume of 3 ml . the resulting labeled antibody sample may be evaluated using dot blot techniques against the lox - 1 antigen with observation of either the fluorescent label or radioactivity depending on the label chosen . the results of this experiment confirm that antibody immunoreactivity is not compromised and that adequate incorporation of label had been accomplished . further characterization by itlc , page gel analysis and whole cell binding of the labeled antibody can be performed as desired . preferred embodiments of the invention now will be explained with reference to the following non - limiting examples . a peptide was conjugated with fluorescein ( fl - kkgg - fqtppql ) and was shown to bind to human endothelial coronary artery cells ( hcaecs ) which are known in the literature to express lox - 1 . an image of hcaecs grown in glass slides treated with this peptide obtained using a fluorescent confocal microsope is shown in fig2 ; the fluorescent image ( shows fluorescently tagged peptide as bright green ) is overlaid with the transmitted light image ( shows outline of cells ). the example reveals that the peptide above was localized on the cells . the experimental conditions for imaging the peptide - labeled hcaecs are described previously . a solution of polyclonal antibody ( igg ) was produced by invitrogen corporation , ( carlsbad , calif .) against the sequence arg - gly - ala - val - tyr - ala - glu - asn - cys - ile at a concentration of 1 . 5 mg / ml . three aliquots containing 250 μg ( 166 μl ) each were transferred to 1 . 5 ml eppendorf tubes and maintained at 0 ° c . the solutions were treated with nahco 3 ( 1m , 20 μl ) and gently inverted . in a separate tube , a solution of 5 - carboxyfluorescein - n - hydroxysuccinate ester in dmf ( 1 mg / ml ) was prepared . the antibody solutions were treated with 5 , 20 or 50 equivalents of the fluorescein / dmf solutions ( 3 . 95 , 15 . 8 and 39 μl respectively ). the highest concentration of dmf was 17 %. the tubes were allowed to warm to room temperature over 1 hour and gently inverted every 15 minutes to assure mixing . during this time pd - 10 columns were equilibrated with pbs and eluted until the sorbent bed was exposed . the entire reaction mixtures were transferred to the columns and eluted with pbs . the fast moving yellow band was clearly visible and was collected in glass scintillation tubes ( approximate eluted volume 3 ml ). the purified labeled antibody samples were then evaluated using a dot blot technique against the lox - 1 antigen ( arg - gly - ala - val - tyr - ala - glu - asn - cys - ile ). an image of hcaecs treated with this fluorescein - labeled polyclonal antibody is shown in fig4 and 5 . the image was obtained using a laser confocal microscope as follows : hcae cells were laid on and grown in wells on a standard commercial 96 - well plate ( becton - dickenson , franklin lakes , n . j .). then , about 10 μl of 1 mg / ml labeled antibody aqueous solution was added to the cells and incubated for 1 hour . subsequently , the cells were washed with pbs buffer three times . after a final wash with buffer , the cells were imaged . images were acquired using an olympus laser scanning confocal microscope , model fluoview 300 , using ar - ion laser ( selecting 488 nm line ) and a 510 - nm long - pass filter . images were acquired using two channels : reflected light and fluorescent mode channel . fig4 is the fluorescent image ( shows fluorescently tagged antibody as bright green ), while fig5 is the transmitted light image ( shows the outline of cells ). this example reveals that the antibody above was localized on the cells . the results of this experiment confirmed that antibody immunoreactivity was not compromised in any of the samples and that adequate incorporation of dye had been accomplished in all cases . further characterization by page gel analysis confirmed protein integrity and that only the 150 kda band contained the fluorescent label . whole cell binding of the labeled antibody was then observed using the previously described binding protocol with hcae cells . the invention has been described with reference to specific embodiments and examples . those skilled in the art appreciate that various modifications may be made to the invention without departing from the spirit and scope thereof .
embodiments of the present invention relates to compounds labeled with imaging agents that also are capable of binding lectin - like oxidized low - density lipoprotein . the labeled compounds are useful for the diagnosis and monitoring of diseases in which inflammation plays a role , such as various cardiovascular diseases including but not limited to atherosclerosis , vulnerable plaque , and coronary artery disease , as well as rheumatoid arthritis .